Clinical investigations into the interplay between cholesterol levels and breast cancer prognosis demonstrated that cholesterol‐lowering medications, primarily statins, effectively diminish the recurrence risk of HR‐positive breast cancer.[36, 37] While many studies have been focused on the role of cholesterol in HR‐positive breast cancer, emerging evidence indicates that aberrant cholesterol biogenesis also promotes TNBC progression.[38, 39, 40] Our study proposes that dual inhibition of CDK4/6 and CDK7 suppresses tumor growth by reducing cholesterol synthesis. This evidence concerns the gene CDK4 and breast carcinoma.